High RIG-I and EFTUD2 expression predicts poor survival in endometrial cancer.
J Cancer Res Clin Oncol
; 149(8): 4293-4303, 2023 Jul.
Article
en En
| MEDLINE
| ID: mdl-36068443
ABSTRACT
PURPOSE:
Endometrial cancer is the most common gynecological malignancy. The helicase RIG-I, a part of the innate immune system, and EFTUD2, a splicing factor which can upregulate RIG-I expression, are shown to influence tumor growth and disease progression in several malignancies. For endometrial cancer, an immunogenic cancer, data about RIG-I and EFTUD2 are still missing. The aim of this study was to examine the expression of RIG-I and EFTUD2 in endometrial cancer.METHODS:
225 specimen of endometrial cancer were immunohistochemically stained for RIG-I and EFTUD2. The results were correlated to clinicopathological data, overall survival (OS) and progression-free survival (PFS).RESULTS:
High RIG-I expression correlated with advanced tumor stages (FIGO p = 0.027; pT p = 0.010) and worse survival rates (OS p = 0.009; PFS p = 0.022). High EFTUD2 expression correlated to worse survival rates (OS p = 0.026; PFS p < 0.001) and was determined to be an independent marker for progression-free survival.CONCLUSION:
Our data suggest that the expression of RIG-I and EFTUD2 correlates with survival data, which makes both a possible therapeutic target in the future.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Endometriales
Tipo de estudio:
Prognostic_studies
/
Risk_factors_studies
Límite:
Female
/
Humans
Idioma:
En
Revista:
J Cancer Res Clin Oncol
Año:
2023
Tipo del documento:
Article
País de afiliación:
Alemania